Skip to main content
SpringerLink
Log in

Molecular Pathogenesis of Prostate Cancer

  • Chapter
  • First Online:
Mechanisms of Molecular Carcinogenesis – Volume 2

  • 803 Accesses

Abstract

With a lifetime risk of 17%, prostate cancer is the second most common malignancy in men. Although the vast majority of patients will have an excellent prognosis, a rapid progression of disease with metastatic spread is seen in some. Therefore, therapy may vary from active surveillance over hormone therapy and chemotherapy to radical prostatectomy. Thus, the molecular heterogeneity of prostate cancer is supposed to alter the tumour’s biological behaviour.

This section starts with a brief introduction of prostate cancer in order to give readers a quick overview. Main signalling pathways, genes and proteins involved in the molecular pathogenesis of prostate cancer will be discussed in the second part. One emphasis is placed on the interactions between the different proteins, genes and signalling pathways. Another focus is on the characterisation of the impact of aberrant molecular profiles on the prognosis of patients with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Mitchell T, Neal DE. The genomic evolution of human prostate cancer. Br J Cancer. 2015;113(2):193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Heidegger I, Massoner P, Sampson N, Klocker H. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Lett. 2015;367(2):113–21.

    Article  CAS  PubMed  Google Scholar 

  4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. In: Kleihues P, Sobin LH, editors. World Health Organization classification of tumours. Lyon, France: IARC Press; 2002.

    Google Scholar 

  6. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125–8.

    CAS  PubMed  Google Scholar 

  7. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.

    Article  CAS  PubMed  Google Scholar 

  8. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387(10013):70–82.

    Article  PubMed  Google Scholar 

  9. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5(2):101–6.

    Article  PubMed  Google Scholar 

  10. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.

    Article  CAS  PubMed  Google Scholar 

  14. Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19(21):5822–7.

    Article  CAS  PubMed  Google Scholar 

  15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  16. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  CAS  Google Scholar 

  17. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005;174(3):1709–16.

    Article  CAS  PubMed  Google Scholar 

  18. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–25.

    Article  CAS  PubMed  Google Scholar 

  19. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O’Neill D, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun. 2007;7:11.

    PubMed  PubMed Central  Google Scholar 

  20. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, et al. Expression of SSX genes in human tumors. Int J Cancer. 1998;77(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  21. Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: characterization of 9 complete genes. Int J Cancer. 2002;101(5):448–53.

    Article  CAS  PubMed  Google Scholar 

  22. Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer. 1997;72(6):965–71.

    Article  CAS  PubMed  Google Scholar 

  23. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005;65(6):2207–15.

    Article  CAS  PubMed  Google Scholar 

  24. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate. 2007;67(16):1781–90.

    Article  CAS  PubMed  Google Scholar 

  25. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 2011;71(21):6785–95.

    Article  CAS  PubMed  Google Scholar 

  26. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother. 2011;34(8):569–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Graham A. Developmental patterning. The Hox code out on a limb. Curr Biol. 1994;4(12):1135–7.

    Article  CAS  PubMed  Google Scholar 

  28. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130(10):2061–9.

    Article  CAS  PubMed  Google Scholar 

  29. Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 2009;36(3):405–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004;64(24):9185–92.

    Article  CAS  PubMed  Google Scholar 

  31. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CF, et al. The role of HOXC6 in prostate cancer development. Prostate. 2015;75(16):1868–76.

    Article  CAS  PubMed  Google Scholar 

  33. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004;101(17):6478–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yu Y, Davicioni E, Triche TJ, Merlino G. The homeoprotein Six1 transcriptionally activates multiple protumorigenic genes but requires Ezrin to promote metastasis. Cancer Res. 2006;66(4):1982–9.

    Article  CAS  PubMed  Google Scholar 

  35. Zeng J, Shi R, Cai CX, Liu XR, Song YB, Wei M, et al. Increased expression of Six1 correlates with progression and prognosis of prostate cancer. Cancer Cell Int. 2015;15:63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20(4):501–34.

    CAS  PubMed  Google Scholar 

  37. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–30.

    Article  CAS  PubMed  Google Scholar 

  38. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate. 1998;35(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  39. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003;23(17):6139–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene. 1998;16(15):1913–20.

    Article  CAS  PubMed  Google Scholar 

  41. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;156(2):585–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, et al. Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer. 2005;93(3):338–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Virmani A, Rathi A, Heda S, Sugio K, Lewis C, Tonk V, et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer. 2003;107(3):341–5.

    Article  CAS  PubMed  Google Scholar 

  44. Kobayashi T, Nakamura E, Shimizu Y, Terada N, Maeno A, Kobori G, et al. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochem Biophys Res Commun. 2009;387(1):196–201.

    Article  CAS  PubMed  Google Scholar 

  45. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9(10):1149–63.

    Article  CAS  PubMed  Google Scholar 

  46. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159(3):941–5.

    Article  CAS  PubMed  Google Scholar 

  47. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22(20):5323–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci. 1998;3:d887–912.

    Article  CAS  PubMed  Google Scholar 

  49. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499–511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hu Y, Li Z, Guo L, Wang L, Zhang L, Cai X, et al. MAGI-2 inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys. 2007;467(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  51. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62.

    Article  CAS  PubMed  Google Scholar 

  52. Mahdian R, Nodouzi V, Asgari M, Rezaie M, Alizadeh J, Yousefi B, et al. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer. Mol Biol Rep. 2014;41(9):6125–31.

    Article  CAS  PubMed  Google Scholar 

  53. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–31.

    Article  CAS  PubMed  Google Scholar 

  54. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857–60.

    Article  CAS  PubMed  Google Scholar 

  55. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2(7):811–4.

    Article  CAS  PubMed  Google Scholar 

  56. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9.

    Article  CAS  PubMed  Google Scholar 

  57. Xue L, Han X, Liu R, Wang Z, Li H, Chen Q, et al. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer. Oncotarget. 2015;7(22):31825–31.

    PubMed Central  Google Scholar 

  58. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196–9.

    Article  CAS  PubMed  Google Scholar 

  59. Katayama H, Sasai K, Kloc M, Brinkley BR, Sen S. Aurora kinase-A regulates kinetochore/chromatin associated microtubule assembly in human cells. Cell Cycle. 2008;7(17):2691–704.

    Article  CAS  PubMed  Google Scholar 

  60. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack Jr RL, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2013;70(4):661–87.

    Article  CAS  PubMed  Google Scholar 

  61. Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev. 2011;31(5):757–93.

    CAS  PubMed  Google Scholar 

  62. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15(1):1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15(1):67–78.

    Article  CAS  PubMed  Google Scholar 

  67. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 2002;16(20):2699–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111–6.

    Article  CAS  PubMed  Google Scholar 

  69. Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C, et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature. 1983;306(5941):395–7.

    Article  CAS  PubMed  Google Scholar 

  70. Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016;35(4):403–14.

    Article  CAS  PubMed  Google Scholar 

  71. Deramaudt TB, Remy P, Stiegler P. Identification of interaction partners for two closely-related members of the ETS protein family, FLI and ERG. Gene. 2001;274(1-2):169–77.

    Article  CAS  PubMed  Google Scholar 

  72. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003;63(14):3877–82.

    CAS  PubMed  Google Scholar 

  73. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.

    Article  CAS  PubMed  Google Scholar 

  74. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011;6(7):e21650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M, et al. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis. 2012;33(12):2558–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol. 2003;17(9):1726–37.

    Article  CAS  PubMed  Google Scholar 

  77. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest. 2003;112(11):1724–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Makela S, Strauss L, Kuiper G, Valve E, Salmi S, Santti R, et al. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol. 2000;170(1–2):219–29.

    CAS  PubMed  Google Scholar 

  79. Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, et al. Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology. 2009;150(1):251–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 2001;61(16):6089–97.

    CAS  PubMed  Google Scholar 

  81. Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2015;70(2):214–8.

    Article  PubMed  CAS  Google Scholar 

  82. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001;159(1):79–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 2004;566(1–3):169–72.

    Article  PubMed  CAS  Google Scholar 

  84. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004;164(6):2003–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Mak P, Li J, Samanta S, Chang C, Jerry DJ, Davis RJ, et al. Prostate tumorigenesis induced by PTEN deletion involves estrogen receptor beta repression. Cell Rep. 2015;10(12):1982–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71(18):6019–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Edwards J, Krishna NS, Mukherjee R, Watters AD, Underwood MA, Bartlett JM. Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU Int. 2001;88(6):633–7.

    Article  CAS  PubMed  Google Scholar 

  88. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10(2):440–8.

    Article  CAS  PubMed  Google Scholar 

  90. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.

    Article  CAS  PubMed  Google Scholar 

  93. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523(7560):347–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 2010;12(5):639–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer. 2014;5(5):265–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.

    Article  CAS  PubMed  Google Scholar 

  98. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008;410(1):1–17.

    Article  CAS  PubMed  Google Scholar 

  99. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–75.

    Article  CAS  PubMed  Google Scholar 

  100. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.

    Article  CAS  PubMed  Google Scholar 

  101. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62.

    Article  CAS  PubMed  Google Scholar 

  102. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans. 2003;31(Pt 3):573–8.

    CAS  PubMed  Google Scholar 

  103. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98(18):10314–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget. 2015;6(39):41976–87.

    PubMed  PubMed Central  Google Scholar 

  106. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–7.

    Article  CAS  PubMed  Google Scholar 

  107. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96(8):4240–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57(22):4997–5000.

    CAS  PubMed  Google Scholar 

  109. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–91.

    Article  CAS  PubMed  Google Scholar 

  111. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12(1):22–9.

    Article  CAS  PubMed  Google Scholar 

  112. Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 2006;66(16):8007–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001;61(10):4222–8.

    CAS  PubMed  Google Scholar 

  114. Guo Y, Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 1998;9(2):185–93.

    CAS  PubMed  Google Scholar 

  115. Yue J, Mulder KM. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-beta. Methods Mol Biol. 2000;142:125–31.

    CAS  PubMed  Google Scholar 

  116. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 2003;63(8):1981–9.

    CAS  PubMed  Google Scholar 

  117. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther. 2000;88(3):229–79.

    Article  CAS  PubMed  Google Scholar 

  118. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, et al. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer. 2011;104(12):1920–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 1997;272(28):17485–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, Medical University of Graz, Graz, Austria

    Maria A. Smolle

  2. Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria

    Maria A. Smolle

  3. Department of Pathology, Medical Faculty, Otto von Guericke University Magdeburg, 39120, Magdeburg, Germany

    Johannes Haybaeck M.D., Ph.D.

  4. Institute of Pathology, Medical University of Graz, 8036, Graz, Austria

    Johannes Haybaeck M.D., Ph.D.

  5. Division of Clinical Oncology, Medical University of Graz, Graz, Austria

    Martin Pichler

Authors
  1. Maria A. Smolle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Haybaeck M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Pichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria A. Smolle .

Editor information

Editors and Affiliations

  1. Department of Pathology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany

    Johannes Haybaeck

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Smolle, M.A., Haybaeck, J., Pichler, M. (2017). Molecular Pathogenesis of Prostate Cancer. In: Haybaeck, J. (eds) Mechanisms of Molecular Carcinogenesis – Volume 2. Springer, Cham. https://doi.org/10.1007/978-3-319-53661-3_9

Download citation

Publish with us

Policies and ethics

Search

Navigation